Company: BDRX
Filing Date: 2025-11-24
Form Type: 424B3
Source: 0001214659-25-017135
Chunk: 11

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-24
Form: 424B3
Chunk 11
---
 which included a payment made to the former advisor on September 29, 2025.

| 6 |

For more information
on recent developments with respect to eRapa, see “—Company Overview.”

Our Pipeline and Platform Technologies

We
are actively pursuing the development of eRapa in FAP and tolimidone in T1D. Due to resource constraints, MTX110 has been de-prioritized
in the three orphan brain cancer indications. Our development pipeline is as follows:

Corporate Information

We
are a public limited company incorporated under the laws of England and Wales under registered number 09216368. Our principal executive
offices are located at 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom. The telephone number at our principal executive
office is +44 29 2048 0180. Our service agent in the United States is located at Puglisi and Associates, 850 Library Avenue Newark, Delaware
19711. Our Depositary Shares, each representing 100,000 Ordinary Shares, are listed on the NASDAQ under the symbol “BDRX.”

Our
corporate website is located at http://biodexapharma.com. The information contained on, or that can be accessed through, our website
is not a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference.

Additional Information

For additional information related to our business and operations,
please refer to the reports incorporated herein by reference, including our Annual Report on Form 20-F for the year ended December 31,
2024, as filed with the SEC on April 11, 2025, and our Reports on Form 6-K, as filed with the SEC, as described in the section titled
“Incorporation of Certain Information by Reference.”

| 7 |

The Offering

| Depositary Shares      
 offered by the Selling 
 Shareholders           |     | Up to an aggregate of 171,700,000 Ordinary Shares of the Company represented                                                                     
 by 1,717 Depositary Shares, issuable upon the exercise of pre-funded warrants, or the December 2023 Private Placement Pre-Funded Warrants,       
 issued in a December 2023 private placement, or the December 2023 Private Placement. The selling shareholders are identified in the table        
 commencing on page 13.                                                                                                                           |
| Ordinary Shares        
 outstanding at         
 November 1, 202